{
    "id": "correct_subsidiary_00055_0",
    "rank": 1,
    "data": {
        "url": "https://mergr.com/nabi-biopharmaceuticals-acquires-univax-biologics",
        "read_more_link": "",
        "language": "en",
        "title": "Nabi Biopharmaceuticals Acquires Univax Biologics",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://mergr.com/home/img/logo-mergr-white.svg",
            "https://mergr.com/home/img/logo-mergr.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "On November 29, 1995, Nabi Biopharmaceuticals acquired life science company Univax Biologics",
        "meta_lang": "",
        "meta_favicon": "https://mergr.com/assets/member/img/favicon.ico",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "Nabi Biopharmaceuticals (NABI) has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction."
    }
}